Hypertension and VEGF-A level correlation in cancer patients starting VEGF inhibitors: A prospective study.

• DOI: 10.1200/jco.2025.43.16_suppl.e16543
• Publication Date: 2025-05-28T14:48:34Z
• Authors: Chandan Krushna Das; Joyita Bharati; Ravimohan Mavuduru; Giridhar Bora; Pratibha Prashar

e16543 Background: Vascular endothelial growth factor inhibitors (VEGFi) are commonly used in cancer therapy. VEGFi can cause hypertension by interference with nitric oxide-mediated vasodilation. The incidence of from varies due to different definitions clinical trials. Understanding the timeline and predictors onset could improve patient management. Methods: This single-center prospective cohort study includes patients without diabetes, hypertension, or proteinuria scheduled for systemic treatment. Serum VEGF-A 24-hour urine were measured at baseline, week 4, 12. Weekly home blood pressure (BP) was assessed weekly 1, 8, Results: Fifty-five (median age 59 years (49.5-66), M:F 1.6:1) included this between January 2021, July 31, 2022. Most had kidney (42, 76%), while others include ovary (n=5), neuroendocrine tumor (n=2), sarcoma (n=3), thyroid liver (n=1), colon (n=1). Sunitinib (n=21), Lenvatinib (n=14), Cabozantinib (n=8), Bevacizumab Axitinib (n=4), Pazopanib (n=3). During follow-up, 2 died, 1 did not report BP. By thirty-nine (70.9%) developed grade HTN (BP 140-159/90-99 mm Hg), increasing 52 (94.5%) 4. median systolic BP (SBP), diastolic (DBP), VEGF-A, protein significantly increase baseline 12 (p < 0.001). DBP correlated positively level 4 (p=0.009, rho=0.35) (p=0.001, rho=0.44). Proteinuria 500 mg/day occurred 31% 45% 12, but no nephrotic range observed. There correlation SBP levels. No found levels Conclusions: Approximately 70% within one starting VEGFi, about half sub-nephrotic after treatment 1. highlights importance early monitoring proteinuria. Further studies should examine development, including biomarkers such as levels, a larger population longer follow-up. Demographic characteristics results weeks. Parameter Median(Range) Baseline 8 p value mmHg 122 (110-133) 140 (100-188) 142 (117-200) 145 (110-198) (121-250) <0.001 75 (60-90) 90 (55-104) (67-110) (75-108) (60-105) (70-120) mg/d (102-256) 400 (180-523) 480 (120-1200) SerumVEGF-A(pg/mL) 304 (172-650) 340 (181-522) 384 (184-570) Creatinine (mg/dL) 0.9 (0.2-1.5) (0.2-2.6) (0.3-2.3) 0.58